The function of interleukin 37 (IL-37; formerly IL-1 family member 7) has remained elusive. Expression of IL-37 in macrophages or epithelial cells almost completely suppressed production of pro-inflammatory cytokines, whereas the abundance of these cytokines increased with silencing of endogenous IL-37 in human blood cells. Anti-inflammatory cytokines were unaffected. Mice with transgenic expression of IL-37 were protected from lipopolysaccharide-induced shock, and showed markedly improved lung and kidney function and reduced liver damage after treatment with lipopolysaccharide. Transgenic mice had lower concentrations of circulating and tissue cytokines (72-95% less) than wild-type mice and showed less dendritic cell activation. IL-37 interacted intracellularly with Smad3 and IL-37-expressing cells and transgenic mice showed less cytokine suppression when endogenous Smad3 was depleted. IL-37 thus emerges as a natural suppressor of innate inflammatory and immune responses.
A r t i c l e s The interleukin 1 (IL-1) family of ligands has 11 members; most are proinflammatory. The receptors, signaling pathways, and functions of the classical family members (IL-1α (A004200), IL-1β (A003663) and IL-18) have been studied extensively. Among the more recently described IL-1 family cytokines, IL-33 (also called IL-1F11) stands apart, as it is the long-sought ligand for the IL-1 receptor family member ST2 (ref. 1). However, knowledge of IL-1F7, which was first identified by in silico research in 2000 (ref.
2), remains limited.
With the exception of the genes for IL-18 and IL-33, the entire human IL1 family maps to the IL-1 family cluster of genes on chromosome 2 (ref. 2) . Comprising 12 β-barrel strands, IL-1F7 shares the structural pattern of the IL-1 family but particularly that of IL-18 (ref. 3) . Although constitutive IL-1F7 mRNA is found in the testis, thymus and uterus, IL-1F7 can be induced in peripheral blood mononuclear cells (PBMCs) and dendritic cells 4 . The protein has been reported in monocytes 5 , tonsil plasma cells and breast carcinoma cells 6 . Five splice variants exist (IL-1F7a-e) 4,7-10 ; IL-1F7b (NM014439) is the largest and includes five of the six exons. None of the isoforms contains a typical signal peptide, but both IL-1F7b and IL-1F7c contain exons 1 and 2, and exon 1 encodes a putative caspase-1 (A000492) cleavage site. In addition, IL-1F7b can form homodimers 6 . IL-1F7 is the only IL-1 family member for which a mouse homolog has yet to be found.
Processing by caspase-1 cleaves the recombinant (r)IL-1F7b precursor into mature IL-1F7b 6 . Both the precursor and mature rIL-1F7b bind to the IL-18 receptor α-chain (IL-18Rα), as shown by immunoprecipitation assays of IL-18Rα:Fc constructs. However, the affinity of IL-18 itself for IL-18Rα is around 50 times higher than that of mature rIL-1F7b 6 . Although mature IL-1F7b binds to IL-18Rα:Fc, rIL-1F7b did not antagonize the activities of IL-18, such as induction of interferon γ (IFN-γ) 5, 6 , and thus is not a receptor antagonist for IL- 18 (ref. 5) . However, consistent with the binding of rIL-1F7b to IL-18Rα, IL-1F7b forms a complex with IL-18 binding protein (IL-18BP; A001254) 5 , the natural antagonist of IL- 18 (ref. 11) . Lower concentrations of IL-18BP inhibit IL-18 activity more effectively than higher concentrations 12 , possibly because of complex formation between IL-1F7b and IL-18BP. Mature IL-1F7b translocates into the nucleus and this process requires caspase-1 (ref. 13) . We therefore proposed that IL-1F7b may act as a cytokine with both intracellular and extracellular functions.
Here we describe a functional role and mechanism of action for IL-1F7. To accomplish this, we either reduced IL-1F7 expression in human PBMCs using small inhibitory RNA (siRNA) or expressed IL-1F7 in human macrophages, epithelial cells and mouse macrophages. We also generated a mouse strain that was transgenic for IL-1F7b and subjected both heterozygous and homozygous mice to non-lethal endotoxic shock. Our results support the idea that IL-1F7 is a natural inhibitor of immune responses. Because of the fundamental nature of these effects, we propose that this member of the IL-1 family should be assigned the name IL-37.
RESULTS

Regulation and function of endogenous IL-37
The functions of endogenous IL-37 and the mechanisms of its regulation are unknown. First, we assessed the steady-state constitutive and inducible abundance of IL-37 protein in PBMCs (Fig. 1a) . The tolllike receptor (TLR) ligands lipopolysaccharide (LPS) and Pam 3 CSK 4 as well as transforming growth factor β 1 (TGF-β 1 ) were highly effective in inducing IL-37 ( Fig. 1a, left) . IL-18, IFN-γ, IL-1β, tumor necrosis factor (TNF) and the dinucleotide CpG also increased synthesis, whereas IL-4 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) inhibited constitutive IL-37 expression.
To investigate the function of endogenous IL-37, we transfected PBMCs from seven donors with concentration-matched pairs of scrambled siRNA or siRNA against IL-37 (siIL-37). The abundance of IL-37 protein in LPS-stimulated PBMCs was considerably reduced by siIL-37 ( Fig. 1b) . In the same cells, treatment with siIL-37 consistently resulted in dose-dependent two-to-threefold increases in the production of mature IL-1β, IL-6 and TNF in PBMCs stimulated with either LPS or Pam 3 CSK 4 (Fig. 1c,d and Supplementary Fig. 1a ). PBMCs were also stimulated with the TLR6-TLR2 ligand MALP-2, which resulted in a similar pattern (data not shown). By contrast, the expression of the anti-inflammatory cytokines IL-10 and IL-1Ra in the same supernatants was unaffected by treatment with siIL-37 ( Fig. 1e and Supplementary Fig. 1b ). We further investigated the effect of reducing endogenous IL-37 in LPS-stimulated PBMCs using an array of 36 cytokines (Fig. 1f) . The array confirmed the results described above; it also revealed changes in the abundance of IL-1α (50% increased) and GM-CSF and G-CSF (2.1-and 2.4-fold increases, respectively).
To investigate the expression of IL-37 in human disease, we carried out immunohistochemistry on synovial tissue from individuals with active rheumatoid arthritis. Diseased synovial lining contained large amounts of IL-37 ( Fig. 1g ; staining with IgG control antibody, 1h). Our results show that the production of IL-37 is induced through pattern recognition and cytokine stimulation and that endogenous IL-37 limits runaway inflammation initiated by innate pathways.
IL-37 abrogates pro-inflammatory cytokines in RAW cells
In a mouse macrophage RAW cell line (RAW-IL-37) that stably expresses the human IL-37b isoform (IL-1F7b) 5, 14 , IL-37b was expressed constitutively in small amounts, but protein expression increased dose dependently upon stimulation with LPS ( Fig. 2a , left). In RAW cells, the molecular weight of IL-37b was 25 kDa; however, endogenous IL-37 in PBMCs migrated at a molecular weight of around 45 kDa ( Fig. 1a) . As the immunoblots were performed under non-reducing conditions, this result is probably due to homodimerization 6 . We determined the specificity of the IL-37 antibody by depletion using excess recombinant IL-37b ( Fig. 1a, right) . 1 0 1 6 VOLUME 11 NUMBER 11 NOVEMBER 2010 nature immunology A r t i c l e s Having confirmed that IL-37b could effectively decrease the production of LPS-stimulated TNF, CXCL2 (a chemokine also known as MIP-2) and IL-1α ( Fig. 2b-d ) as compared with mock-transfected RAW cells, we tested an array of 40 mouse cytokines, chemokines and other inflammatory mediators. In RAW-IL-37 cells, the expression of several major cytokines including IL-1α and IL-6 were almost completely suppressed (by 88% and 86%, respectively; Fig. 2e ). The production of M-CSF, the chemokine CXCL13 (BCA-1), GM-CSF and IL-1β was considerably (55-62%) reduced, and the production of the chemokine CCL12 (MCP-5), IL-23 and IL-1Ra were also lower. The mean changes in other molecules were below 30% ( Fig. 2e) . The stimulation of RAW-IL-37 cells with IL-1β or TNF caused similar reductions in the expression of IL-1α, TNF and CXCL2 (data not shown).
Various TLR ligands induced the production of IL-37b in RAW-IL-37 cells ( Fig. 2a , right). Pronounced reductions in the expression of IL-1α, MIP-2, TNF and IL-6 (by up to 99, 97, 92 and 98%, respectively) also occurred in RAW-IL-37 cells when stimulated by various TLR ligands ( Supplementary Table 1 ). Therefore, the expression of IL-37b in murine RAW macrophages reduced the production of TLR-induced pro-inflammatory cytokines.
IL-37 reduces cytokines in monocytic and epithelial cells
The human monocytic cell line THP-1 was transiently transfected with a pIRES vector controlled by a constitutively active cytomegalovirus (CMV) promoter that contained full-length IL-37b linked to a FLAG tag at its C terminus. The vector also contained a green fluorescence protein (GFP)-coding sequence. The expression of IL-37b significantly reduced spontaneous and LPS-induced expression of IL-1α, IL-1β, TNF and IL-8 in undifferentiated (Fig. 3a,b and Supplementary Fig. 2a ) and phorbol ester (PMA)-differentiated 15 THP-1 cells (human monocytic (leukemia) cells) ( Fig. 3c and Supplementary Fig. 2b,c) . IL-37b also suppressed IL-1β-induced expression of IL-1α, IL-8 and TNF (Fig. 3b,c and Supplementary Fig. 2a,c) .
Steady-state IL-37 mRNA is found in tissues rich in epithelial cells 4 . Hence, we transfected the epithelial cell line A549 with the pIRES-IL-37b plasmid (immunofluorescence in Supplementary Fig. 2d , immunoblot in Fig. 3d ). Constitutive and IL-1β-induced production of IL-6 and IL-1α was reduced (by 43% for constitutive IL-6; 47% for IL-1β-induced IL-6; 34% for constitutive IL-1α; and 42% for IL-1β-induced IL-1α; Fig. 3e the results of vector-mediated expression of IL-37b in RAW cells and silencing of endogenous IL-37 in PBMCs.
Smad3 and IL-37 form a functional complex IL-37 was identified in a proteomics-based search for proteins that interacted with Smad3 (ref. 16 ). Therefore, we transfected human A549 cells with FLAG-tagged IL-37b and used immunofluorescence to show that IL-37b colocalized with phospho-Smad3 ( Fig. 4a , bright yellow in the overlay). Both IL-37b and phospho-Smad3 were induced by IL-1β and most prominently stained in perinuclear and cytosolic regions (see Supplementary Fig. 3 for control images). We also showed the formation of an IL-37b-Smad3 complex using anti-FLAG immunoprecipitation (Fig. 4b) . The presence of more than one band is probably due to alternate splicing of Smad3 (ref. 17 ). Next, we tested the hypothesis that Smad3 is required for IL-37 activity. We used the specific inhibitor SIS3 (ref. 18) to block the activation of Smad3 and found that it dose dependently reversed the inhibition of IL-6 and IL-1α expression in the LPS-stimulated RAW-IL-37 cells ( Fig. 4c and Supplementary Fig. 4 ). Under the same conditions, SIS3 had no effect in mock-transfected RAW cells. We then evaluated the IL-37b-Smad3 interactions in THP-1 cells. The SIS3-induced increases in IL-1β expression were significantly greater when high concentrations of IL-37b were present ( Fig. 4d) . By immunofluorescence, we found that there was similar colocalization of IL-37b and Smad3 in THP-1 cells as there was in A549 cells (data not shown).
We then generated stable THP-1 clones depleted of Smad3 by using a lentiviral short hairpin RNA (shRNA) coding for Smad3 (which decreased Smad3 mRNA to roughly 12% of that of scrambled siRNAtransfected clones (data not shown); for protein knockdown, see Supplementary Fig. 5 ). In these cells, the ability of IL-37b to reduce IL-1β-or LPS-induced production of IL-8 ( Fig. 4e) , IL-6 and TNF (data not shown) was considerably reduced. These in vitro findings were confirmed in vivo as described below.
Post-receptor signal transduction in the presence of IL-37
We transfected THP-1 cells with IL-37b and treated them with LPS plus IFN-γ. We then measured the activation of 37 kinases by this treatment. Regulators of cellular adhesion and migration, namely focal adhesion kinase (FAK), proline-rich tyrosine kinase 2 (Pyk2) and paxillin, were suppressed by up to 78% (Supplementary Fig. 6 ). Expression of the MAP kinase p38α was reduced by 51% and the expression of multiple STAT transcription factors (hematopoietic cell kinase (Hck), p53 and target of rapamycin (TOR)) were also lower in IL-37b-transfected cells than in controls.
Because changes in kinases affect cellular proliferation and differentiation, we assessed live-cell images from RAW-IL-37 and mock-transfected RAW cells. We observed striking morphological differences in cells transfected with IL-37b. For example, whereas mock-transfected RAW cells formed pseudopodia, RAW-IL-37 cells almost never did so ( Supplementary Fig. 7a (arrows), b) . Moreover, Fig. 7c , arrows) but not in RAW-IL-37 cells. Treatment of the cells with TLR ligands 1-6 and 9 produced similar results (data not shown). Our results show that IL-37b regulates post-receptor signal transduction in a specific fashion and that these effects result not only in a reduction in pro-inflammatory cytokine production but also in morphological changes in RAW cells.
IL-37 protects mice from LPS-induced shock
To investigate whether IL-37 suppresses innate responses to LPS in vivo, we generated a line of mice that were transgenic for FLAGtagged IL-37b (IL-37tg). The presence or absence of IL-37b protein in IL-37tg or PCR-negative littermates was confirmed by FLAG immunoprecipitation and IL-37 staining of splenocytes as well as by IL-37 immunoblots on white blood cell lysates (Fig. 5a,b) . Similar to the in vitro results, uninduced, steady-state production of IL-37b in vivo was low despite the constitutively active CMV promoter. Synthesis of IL-37b was augmented by LPS administration. Outside of experimental settings, the IL-37tg colony did not differ from negative or wild-type mice: growth, behavior, reproduction and male-to-female ratio were normal over many generations. We induced non-lethal endotoxic shock in IL-37tg mice, negative littermates and wild-type mice by injecting 10 mg/kg LPS intraperitoneally. We did not find any differences between negative littermates and wild-type mice; thus, these two groups are shown as one (hereafter designated as neg-WT). To establish normal values in this model, we treated additional mice from each group with vehicle only. In this group, we found no difference in any parameter between IL-37tg and neg-WT mice. Compared to neg-WT mice, the effects of endotoxemia were markedly attenuated in the IL-37tg mice (Fig. 5c-k) . LPS-induced hypothermia was weaker in IL-37tg mice, with the effect being most pronounced in homozygotes (Fig. 5c) . IL-37tg mice also achieved respiratory compensation of the metabolic acidosis induced by LPS. For example, pH and HCO 3 were higher, pCO 2 was lower and the base excess was less negative in IL-37tg mice than in neg-WT mice ( Fig. 5d-g) . IL-37tg mice were less dehydrated, as blood sodium concentrations were not significantly different from those of vehicle-treated control mice (Fig. 5h) . Likewise, IL-37b conferred protection against a rise in potassium concentrations, which in neg-WT mice reached nearly 6 mmol/l after LPS challenge (Fig. 5i) . Moreover, LPS-induced liver damage, as measured by increased alanine aminotransferase (ALT), was prevented in IL-37tg mice as the plasma activity of this enzyme was close to that in vehicle-injected control animals ( Fig. 5j) . Similar results were obtained for aspartate aminotransferase (AST) (Fig. 5k) .
These physiological findings in IL-37tg mice were accompanied by a reduction in various cytokines in different compartments as compared with control mice similarly challenged by LPS ( Figs. 6 and 7) . In the plasma, we found reduced concentrations (up to 65% reduction compared with controls) of IL-6, IL-1β, IL-17 and IFN-γ in heterozygous IL-37tg mice, whereas in homozygotes these cytokines were nearly absent (72-95% reduction; Fig. 6b,c) . A cytokine protein array analysis revealed that 18 cytokines were reduced by more than 33% in IL-37tg mice, 16 of which were pro-inflammatory ( Fig. 6a) . Among the cytokines that were found in similar abundance in the plasma of IL-37tg and neg-WT mice were the anti-inflammatory cytokines I-309, IL-13 and IL-10. These findings, together with the finding that IL-4 and IL-27 showed on average up to 2.5-fold increased concentrations in the plasma of IL-37tg mice, show that IL-37b expression results in specific modulation of the immune response to LPS. These data are consistent with the suppression of cytokine production in cells transfected with IL-37b.
The amounts of pro-inflammatory cytokines and chemokines in the spleens and lungs of IL-37tg mice were also lower than in organs from (Figs. 6d,e and 7a) . With the exception of splenic expression of IL-1α, the pattern of cytokine regulation in the organs and the systemic circulation was similar. In contrast to the pro-inflammatory cytokines, the immunosuppressive TGF-β 1 was not reduced but rather increased by 1.8-fold in the spleens of IL-37tg mice.
As the anti-inflammatory activity of IL-37b was not limited to cytokines of innate immunity, we investigated whether IL-37b affected the function of dendritic cells (DCs), which coordinate immune responses. Among the splenocytes from the mice shown in Figure 6 , we identified CD11c + DCs and assessed their activation status by measuring the surface expression of CD86 (B7-2, a costimulatory molecule that facilitates T cell activation) and MHC class II (a stimulator of CD4 + T cells). The presence of IL-37b conferred a marked reduction in LPS-induced DC activation (Fig. 7b,c) . Whereas in LPS-injected neg-WT mice the average expression of CD86 and MHC II on DCs was 73%, with a range from 46-89%, the average expression on IL-37tg homozygotes was only 47% CD86 + MHC II + with a range from 18-69%, indicating that fewer DCs were activated by LPS in IL-37tg mice than in neg-WT mice. Consistent with previous data (for example, ref. 19) , DCs in vehicle-treated mice were about 40% CD86 + MHC II + with no difference between neg-WT mice, IL-37tg heterozygotes and IL-37tg homozygotes. Thus, IL-37b reduced the number of activated DCs in LPS-treated mice to near constitutive background. We also measured the activation of macrophages, which showed similar but less pronounced inhibition (data not shown). The total numbers of DCs, macrophages (F4/80 + ), natural killer cells (NK1-1 + ) and CD4 + T cells were similar in all strains and experimental conditions (not shown). In cultures of fresh whole blood from the mice, the production of IL-6 and TNF induced by LPS, LPS plus IL-12, IL-1β, TNF or IL-12 plus IL-18 was up to 86% lower in IL-37tg mice than in neg-WT mice (Fig. 7d,e) . Hence, the anti-inflammatory functions of IL-37 are also observed in various conditions in vivo. By suppressing pro-but sparing anti-inflammatory cytokines and by inhibiting DC activation, IL-37b protected the lung, kidney, and liver in a model of endotoxic shock.
Smad3 knockdown in vivo reduces the activity of IL-37
To show that Smad3 contributes to the function of IL-37 in vivo, we used siRNA to silence Smad3 in the lungs of IL-37tg and neg-WT mice. Effective knockdown was determined by immunoblotting ( Fig. 8a) . Cytokine assays on the same lysates showed that the anti-inflammatory function of IL-37 was considerably reduced when Smad3 was silenced (Fig. 8b,c) . Whereas IL-1β protein abundance was 94% lower in IL-37tg mice than in controls when scrambled siRNA was inhaled, this reduction was only 63% when Smad3 was silenced. For IL-17 expression, IL-37b reduced the protein concentration from 40.4 to 5.8 pg per mg total protein (86%) with scrambled siRNA but only from 53.3 to 35.7 pg per mg total protein (33%) when the mice inhaled siRNA to Smad3. The effect of siRNA to Smad3 was a 1.5-to 2.4-fold increase in cytokine production in neg-WT mice, compared with an up to 15-fold increase in IL-37tg mice. These experiments corroborate the functional link between IL-37 and Smad3 but are also relevant to the anti-inflammatory portfolio of TGF-β.
DISCUSSION
Since the first description of IL-37 (IL-1F7) in 2000 (ref. 8 ), there has been no report on the function of endogenous IL-37. Here the use of siRNA to reduce synthesis of IL-37 protein in PBMCs increased the production of several pro-inflammatory mediators, including IL-1α, IL-1β, IL-6, IL-12, G-SCF, GM-CSF and TNF. The expression of the anti-inflammatory IL-1Ra and IL-10 in the same cultures was unaffected. These data suggest that IL-37 acts as a negative feedback inhibitor of inflammatory responses and that this function does not depend on anti-inflammatory cytokines such as IL-10. As several TLR ligands as well as IL-1β, TNF, IFN-γ and IL-18 induce the expression of IL-37, the siRNA data suggest that the mitigating activity of this cytokine affects a wide spectrum of inflammatory assaults. It is not unexpected that inflammation induces anti-inflammatory mechanisms to limit damage. Therefore, the observations that, in general, IL-37 is not constitutively expressed in tissues from healthy subjects but expression is high in synovial tissue from patients with rheumatoid arthritis are in accord with the concept that IL-37 mediates a negative feedback mechanism to curb excessive inflammation.
Low concentrations of the immunoregulatory cytokine TGF-β 1 could induce endogenous IL-37, which is relevant to the interaction of IL-37 with Smad3. In a study designed to identify intracellular candidates that bind to Smad3 using two-dimensional gel electrophoresis and mass spectrometry, the only cytokine among the proteins that bound Smad3 was IL-37 (ref. 16) . Smad proteins are the main intracellular signaling effectors of TGF-β and are phosphorylated by TGF-β receptors upon binding the ligand. After phosphorylation, Smad3 translocates to the nucleus and affects gene transcription. For example, binding of Smad3 to DNA inhibits the activation of DCs and macrophages 20, 21 , skews T cells toward tolerance 22 and inhibits cellular cytotoxicity 23 . IL-37b translocates to the nucleus 13 and here it is bound to both non-phosphorylated and phosphorylated Smad3 in A549 and THP-1 cells, each of which is consistent with the intracellular complex of Smad3-IL-37 identified by mass spectrometry 16 . We tested the functionality of this complex by using a specific inhibitor of Smad3 in RAW and THP-1 cells and siRNA to Smad3 in vitro. In vivo, silencing endogenous Smad3 significantly reduced the anti-inflammatory properties of IL-37b.
We conclude that IL-37 functions, at least in part, with Smad3, and thereby facilitates the cytokine-suppressing properties of TGF-β (ref. 24) . Foremost, TGF-β is well established as an inhibitor of DC function. For example, TGF-β and the downstream activation of the Smad pathway were required for T reg cell-mediated suppression of DC function, including expression of CD86 and production of proinflammatory cytokines, in a mouse model of leukemia 25 . In other studies, blockade of TGF-β resulted in reduced capacity for antigen presentation 26 or costimulation 27 in human DCs in vitro; it also caused a reduction in IL-12 production and in the stimulation of T cell proliferation by human monocyte-derived DCs 28 . In vivo, functional inactivation of the TGF-β receptor (and hence TGF-β signaling) in DCs resulted in increased production of T helper type 1 (T H 1) and T H 17 cytokines and aggravation of autoimmune encephalomyelitis 29 . These data concur with the ability of IL-37b to suppress both DC function and cytokine regulation, the latter including the elimination of the low background expression of natural IL-37 by IL-4 and GM-CSF and the pronounced effect of IL-37 on GM-CSF. Supplementary Table 3 .
A r t i c l e s
The concept that IL-37 acts by an intracellular mechanism in translocating to the nucleus is not new in cytokine biology. For example, IL-1α is found in the nucleus and affects the transcriptional machinery 30, 31 . IL-33 also functions as an endothelial transcription factor 32 . Outside the IL-1 family, IL-16 (ref. 33) , high-mobility group box chromosomal protein 1 (ref. 34) , and macrophage migration inhibitory factor (MIF) 35 are examples of cytokines that have intracellular activities. However, these cytokines also have a second function; released from the cell, they trigger their cognate cell-surface receptor. Although recombinant IL-37 has been reported to bind to 6) , IL-37 does not seem to function as a receptor antagonist for IL-18. However, in the presence of low concentrations of IL-18 binding protein, recombinant IL-37 reduces the induction of IFN-γ by IL-18 (ref. 5).
As anticipated from the increases in pro-inflammatory cytokines when endogenous IL-37 is inhibited using siRNA, several LPS-and IL-1β-induced pro-inflammatory cytokines were markedly decreased in human and macrophages (the cell type in which most previous studies on IL-37 have been conducted [4] [5] [6] 13, 14 ). As IL-37 is naturally expressed in organs that contain epithelial cells 4,6 , we transfected human lung epithelial cells and confirmed that IL-37 was active in this model. This extension of IL-37 activity to include IL-1-mediated signals in epithelia is relevant, as stimulation by IL-1β and downstream effector functions of IL-6 constitute major pro-inflammatory insults for epithelial cells 36 .
Despite the presence of the constitutively active CMV promoter, there were only small amounts of IL-37b protein under steady-state conditions in vitro and in vivo, but the amounts markedly increased with an inflammatory challenge. Consequently, IL-37b-mediated reductions in cytokines were also seen only during inflammation. This observation is consistent with the presence of a coding region instability element in the mRNA for IL-37b that can be overcome by exogenous stimulation, resulting in stabilization of the mRNA and synthesis of IL-37b protein 14 . We therefore infer that the suppression of pro-inflammatory cytokines by IL-37 is undesirable under resting conditions and in the early stages of innate immune responses, but that later, when increasing danger is sensed, the expression of IL-37 prevents an excessive inflammatory response.
Among the kinases whose phosphorylation was suppressed by IL-37b expression were STATs 1-4, which are involved in signal transduction for pro-inflammatory cytokines such as IL-6, IL-12 and IFN-γ (ref. 37) . Their deactivation represents a straightforward mechanism by which IL-37 can attenuate inflammation; furthermore, this idea is consistent with the formation of a functional IL-37-Smad3 complex, as Smad3 mostly antagonizes STAT1 and STAT3 (refs. 38,39) . The same is true for the reduction of c-Jun, which is part of the IL-1-inducible pro-inflammatory transcription factor AP-1 (ref. 40) and is inhibited by TGF-β (ref. 41 ). The expression of IL-37b also reduced phosphorylation of p38 MAPK, which holds a central position in several, predominantly pro-inflammatory, signaling cascades 42 . Furthermore, phosphorylation of GSK-3α/β is increased by expression of IL-37b, which renders this kinase inactive. Remarkably, such inhibition of GSK-3 activity skews monocytes triggered by TLR ligands away from secreting pro-inflammatory cytokines and toward producing IL-10 (ref. 43) .
To assess IL-37 in vivo, we generated a mouse strain that was transgenic for human IL-37b. Both heterozygous and homozygous IL-37tg mice were protected from non-lethal LPS-induced endotoxic shock (shown by a reduction in hypothermia and lung, liver and kidney disease), although most of the effects were more pronounced in homozygotes. This protection was afforded through a marked reduction in the amount of pro-inflammatory cytokines in the lungs, spleen and plasma, as well as through suppression of DC activation by IL-37b, and was, at least in part, mediated by Smad3. These data provide evidence that IL-37 has a major role in vivo. These findings resemble a report that asserted an essential role for TGF-β and Smad3 in protection against excessive inflammation after an endotoxin challenge 44 . In that study, Tgfb1 −/− and Smad3 −/− mice showed higher expression of IL-1β, TNF and inducible nitric oxide synthase (iNOS) in liver, lung and heart tissue, as well as increased NF-κB activation and higher levels of NO in the plasma, ultimately resulting in hyperresponsiveness to LPS. The similarities between these data and our results indicate that the IL-37-Smad3 complex is relevant in vivo.
To investigate whether the protective functions of IL-37 extend beyond LPS in a whole animal model as they did in vitro, we stimulated whole blood from IL-37tg and control mice with IL-1β, TNF, IL-12 plus IL-18, and IL-12 plus LPS. The pro-inflammatory effect of each of the stimuli was markedly suppressed by IL-37b. Together with the Smad3-associated mechanism of action, these findings are consistent with the ability of IL-37b to inhibit DC function. DCs receive, integrate and pass on signals from and to a wide variety of cells and thus constitute part of the interface between innate and adaptive immunity. It is likely that by reducing surface expression of the costimulatory molecule CD86 (B7-2) and MHC II (a major activator of CD4 + T cells) on DCs along with propagating an anti-inflammatory cytokine environment, IL-37 attenuates T cell responses. The suppression of DC activation in vivo is also consistent with the IL-37-mediated inhibition of M-CSF and GM-CSF, and the reduction in differentiation and activation of RAW cells.
We conclude that endogenous IL-37 suppresses immune responses by shifting the cytokine equilibrium away from excessive inflammation. This function is achieved at least in part by inhibition of DC activation on the cellular level and by interaction with Smad3 and modulation of kinase checkpoints on the molecular level. The protective activity of IL-37 can be observed in vitro as well as in vivo and affects a broad spectrum of pro-inflammatory insults such as TLR ligands, IL-1β, TNF and IL-12 plus IL-18, placing this cytokine as a new member in the portfolio of classical anti-inflammatory cytokines, such as IL-10 and TGF-β.
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